News

"We are excited about the establishment of an ADR program as it should attract new US investors. In addition, the ADR program will assist Radiopharm in completing its proposed Nasdaq listing that was announced on 26 July 2024," said Riccardo Canevari, CEO and managing director of Radiopharm.

AusBiotech and MTPConnect have announced a new partnership to deliver Australia’s first National Biotech and Medtech Development and Commercialisation Summit, to be held in Canberra on 19 November 2024.  

Invion (ASX:IVX) has announced that RMW Cho Group, the licensor of the Photosoft technology, has completed a Phase 2 prostate cancer trial using a sublingual formulation of INV043.

Cochlear (ASX:COH) has announced that Sarah Thom will be its chief financial officer, effective 1 January 2025.

New research findings reveal that people who inherit a genetic biomarker known to predict poorer outcomes with routine prostate cancer treatment could be successfully treated and have better survival outcomes with personalised hormonal therapy.

As the father of Australian biotech, Leon Serry AM is remembered for his pioneering work as an investor and philanthropist founding Cicardian (now Opthea Ltd), establishing the foundation of Australia’s biotech investment industry.

PharmAust (ASX:PAA) says it has completed a pre-submission meeting with the European Medicines Agency and the Committee for Orphan Medicinal Products and has submitted a request for orphan designation for monepantel for the treatment of amyotrophic lateral sclerosis.

Magellan Stem Cells has welcomed a $7 million grant from the federal government’s Medical Research Future Fund to help fund a Phase 3 human trial of the company’s donor stem cell treatment for osteoarthritis.

Monash University researchers have discovered a blood cell that, when introduced to a bone, muscle, or skin injury, has the potential to promote rapid healing.

Immutep (ASX:IMM) has announced positive efficacy and safety results from the TACTI-003 Phase 2b trial evaluating its eftilagimod alpha in combination with MSD’s KEYTRUDA.

Thanks to a $10 million donation, Cabrini Health, in partnership with Monash University, is aiming to transform cancer care for Victorians.

The Federal Government has released the final report of the Health Technology Assessment (HTA) Review, marking the first comprehensive review of Australia’s HTA system in nearly 30 years.